Anlon Healthcare LimitedQ1 FY27 Results & Financial Update
Anlon Healthcare Limited: Q1 FY27 consolidated results and company financials – revenue ₹87.56 Cr, PAT ₹8.28 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Anlon Healthcare price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Anlon Healthcare Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Operating profitability also scaled substantially, with consolidated EBITDA reaching ₹15.65 crore in Q1 FY27, reflecting a 150.14% increase from ₹6.26 crore reported in the corresponding quarter of the previous fiscal year. The company's reported EBITDA margin stood at 17.86% for the quarter, compared to 18.78% in Q1 FY26, while PAT margin was reported at 9.45% against 10.66% previously.
A major operational highlight during the quarter was the completion of the acquisition of a 63.98% stake in Remember India Health Links Pvt. Ltd. on May 8, 2026, for a cash consideration of ₹5.38 crore. This transaction established Remember India as a subsidiary of Anlon Healthcare and marked the company's strategic entry into the Finished Dosage Formulations (FDF) segment, granting access to more than 30 formulation dossiers.
The integration of recent subsidiaries alongside core API operations broadened Anlon's reach across B2B API channels, domestic retail markets, and hospital segments. Management noted that these strategic investments are designed to create meaningful operational synergies, streamline manufacturing and quality control processes, and enhance long-term scalability across the pharmaceutical value chain.
Total expenditure for the quarter rose to ₹71.97 crore, driven primarily by higher raw material expenses of ₹66.08 crore, reflecting the scale-up in business volume and expanded operational footprint. Employee benefits expense stood at ₹1.95 crore, while other expenses were recorded at ₹3.94 crore, reflecting increased administrative and operational activity following recent corporate transactions.
Financing costs and depreciation rose moderately in tandem with expanded asset bases and business scope, with finance costs recorded at ₹0.92 crore and depreciation and amortization expenses at ₹1.07 crore. PBT for the quarter closed at ₹13.66 crore after accounting for other income of ₹0.06 crore, resulting in a tax provision of ₹5.38 crore.
Profit after tax was ₹8.28 Cr for the reported quarter. EPS was ₹0.16 for the reported quarter.
01 · Business model
What does Anlon Healthcare do?
Incorporated in 2013 and headquartered in Rajkot, Gujarat, Anlon Healthcare Limited is a research-driven chemical and pharmaceutical manufacturer. The company specializes in producing high-purity pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and advanced chemical solutions that serve as foundational raw materials for finished dosage formulations.
Anlon is positioned among a select group of Indian manufacturers of critical non-steroidal anti-inflammatory drugs (NSAIDs) and specialized pain management agents, notably Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol. Its chemical and API products find diverse applications across the pharmaceutical, nutraceutical, veterinary, and personal care sectors.
The company's commercial and technical infrastructure includes manufacturing facilities located in Gujarat supported by in-house research and development centers. Anlon operates across more than 15 international countries, catering to global formulators and domestic healthcare markets through an expanding network of regulatory filings and global quality certifications.
To transition from an API-focused manufacturer into an integrated pharmaceutical enterprise, Anlon has pursued strategic inorganic growth through acquisitions. These corporate additions integrate finished dosage formulation capabilities, raw material synthesis, and dedicated process development, allowing the company to capture broader margins across the pharmaceutical value chain.
02 · Historical context
What shaped the business before this quarter
Incorporated originally as Anlon Ventures Private Limited in Rajkot, Gujarat, before later changing its name to Anlon Healthcare Private Limited.
Commenced commercial production of pharmaceutical intermediates and APIs, exported its first batch to South Korea, and secured initial GMP and foreign manufacturer accreditations.
Received WHO-GMP certification for its manufacturing facility, establishing baseline compliance for broader international export markets.
Received Drug Master File (DMF) approval from the Brazilian Health Regulatory Agency (ANVISA) for Loxoprofen Sodium Dihydrate and converted to a public limited company, renaming itself Anlon Healthcare Limited.
Successfully completed its initial public offering and listed its equity shares on BSE and NSE.
Expanded its corporate group by acquiring stakes in Apiqo Organics Pvt. Ltd., Bizotic Lifescience Pvt. Ltd., and Remember India Health Links Pvt. Ltd. to build an integrated manufacturing and formulation platform.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹87.56 Cr |
| Total income | ₹87.62 Cr |
| Profit before tax | ₹13.66 Cr |
| Profit after tax | ₹8.28 Cr |
| EPS | ₹0.16 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Higher volume demand from global formulators for specialized NSAID APIs, including Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol.
Entry into the FDF segment following the acquisition of Remember India Health Links, adding commercialized formulation dossiers and expanding into domestic retail and hospital markets.
Expanded sales momentum across operations spanning more than 15 countries, driven by regulatory compliance and established global distribution networks.
What drove margins
Raw material expenses scaled to ₹66.08 crore in Q1 FY27, reflecting increased procurement volume to support higher production levels across manufacturing units.
Integration of upstream acquisitions like Apiqo Organics and Bizotic Lifescience designed to secure internal supply chains for critical intermediates and support long-term EBITDA margin targets of 25% to 30%.
Fixed cost dilution across higher aggregate revenue streams, partially offset by increased employee benefit expenses of ₹1.95 crore and other operational costs of ₹3.94 crore.
05 · Demand, customers & order book
Where demand is coming from
Served 125 customers directly and indirectly across global markets, supported by zero order cancellations and multi-year relationships with key formulators.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Continued to form the core of standalone revenue contribution, supplemented by ongoing scale-up in industrial and fine chemical segments.
Established via the acquisition of Remember India Health Links, adding 30+ formulation dossiers covering tablets, capsules, and specialized pharmaceutical preparations.
Geography and market mix
Maintained active commercial operations and regulatory filings across 15+ countries, backed by DMF submissions with global health authorities including EDQM Europe, ANVISA Brazil, and NMPA China.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Maintained a combined installed production capacity of 1,400 to 1,600 MTPA across dedicated manufacturing blocks in Rajkot.
Operating capacity utilization was reported at 62.37%, supported by glass-lined and stainless steel reactors ranging from 20L to 200L scale-up assemblies.
Projects, capex and execution
Integrated ready-to-operate manufacturing facilities acquired through Bizotic Lifescience and Apiqo Organics to bypass greenfield execution risks and accelerate operational readiness.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Transitioning from a pure-play API supplier into an integrated pharmaceutical company encompassing KSMs, intermediates, APIs, and finished dosage formulations.
Advancing custom manufacturing and development (CDMO) projects, including 3 molecules currently under development for 2 global innovator companies.
09 · Reported developments
What changed operationally
Delivered triple-digit year-on-year growth in total income (+163.02%), EBITDA (+150.14%), and PAT (+133.13%) for Q1 FY27.
Completed the acquisition of a 63.98% stake in Remember India Health Links for ₹5.38 crore, successfully entering the FDF segment.
10 · Management guidance & targets
What management is targeting from here
Management stated confidence in achieving a long-term revenue CAGR of approximately 30% over the next three years, while maintaining EBITDA margins in the range of 25% to 30%.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Acquisition Completion
Completed the acquisition of Remember India Health Links Pvt. Ltd. on May 8, 2026, making it a subsidiary of Anlon Healthcare.
12 · Key Q&A
The quarter, answered directly
What does Anlon Healthcare do?
Incorporated in 2013 and headquartered in Rajkot, Gujarat, Anlon Healthcare Limited is a research-driven chemical and pharmaceutical manufacturer. The company specializes in producing high-purity pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and advanced chemical solutions that serve as foundational raw materials for finished dosage formulations.
What is the clearest takeaway from Q1 FY27?
Operating profitability also scaled substantially, with consolidated EBITDA reaching ₹15.65 crore in Q1 FY27, reflecting a 150.14% increase from ₹6.26 crore reported in the corresponding quarter of the previous fiscal year. The company's reported EBITDA margin stood at 17.86% for the quarter, compared to 18.78% in Q1 FY26, while PAT margin was reported at 9.45% against 10.66% previously.
What drove revenue or demand?
Higher volume demand from global formulators for specialized NSAID APIs, including Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol.
What mattered most for margins or profitability?
Raw material expenses scaled to ₹66.08 crore in Q1 FY27, reflecting increased procurement volume to support higher production levels across manufacturing units.
What changed operationally beyond the headline numbers?
Maintained a combined installed production capacity of 1,400 to 1,600 MTPA across dedicated manufacturing blocks in Rajkot.
What is management guiding or targeting from here?
Management stated confidence in achieving a long-term revenue CAGR of approximately 30% over the next three years, while maintaining EBITDA margins in the range of 25% to 30%.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsidiary Integration: Monitor the operational and financial integration of Remember India Health Links and other acquired entities into consolidated results.
- 02
Regulatory Progress: Track upcoming DMF filings and regulatory approvals across target international jurisdictions including the US and Europe.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.